Immune Design Corp. (NASDAQ:IMDZ) Director Franklin M. Berger acquired 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were purchased at an average price of $4.58 per share, with a total value of $114,500.00. Following the completion of the acquisition, the director now owns 75,000 shares of the company’s stock, valued at approximately $343,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.11. Immune Design Corp. had a negative net margin of 324.33% and a negative return on equity of 59.14%. The firm had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $0.62 million.
Large investors have recently modified their holdings of the business. State of Wisconsin Investment Board bought a new stake in Immune Design Corp. during the 2nd quarter worth about $117,000. Alliancebernstein L.P. bought a new stake in Immune Design Corp. during the 2nd quarter worth about $118,000. Bank of America Corp DE lifted its position in Immune Design Corp. by 123.3% during the 1st quarter. Bank of America Corp DE now owns 15,246 shares of the biotechnology company’s stock worth $104,000 after buying an additional 8,418 shares in the last quarter. Virtu KCG Holdings LLC bought a new stake in Immune Design Corp. during the 2nd quarter worth about $153,000. Finally, Dimensional Fund Advisors LP lifted its position in Immune Design Corp. by 9.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 18,896 shares of the biotechnology company’s stock worth $184,000 after buying an additional 1,600 shares in the last quarter. 51.44% of the stock is currently owned by hedge funds and other institutional investors.
IMDZ has been the topic of several analyst reports. ValuEngine downgraded shares of Immune Design Corp. from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd. BidaskClub downgraded shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Wells Fargo & Company downgraded shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $29.00 to $10.00 in a research report on Tuesday, October 17th. Zacks Investment Research raised shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Tuesday, July 18th. Finally, Royal Bank Of Canada initiated coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company’s stock. Immune Design Corp. has a consensus rating of “Buy” and an average price target of $14.75.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
What are top analysts saying about Immune Design Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immune Design Corp. and related companies.